Table 2 Fasting PCSK9 and lipid levels pre- and post-atorvastatin treatment
From: Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
Baseline | Treatment | % Change | |
|---|---|---|---|
PCSK9 (μg/mL) | 5.88 ± 1.70 | 6.32 ± 2.29* | 7.40 ± 25.3 |
Total cholesterol | 5.82 ± 0.76 | 4.37 ± 0.62*** | -25.0 ± 9.06 |
Triglycerides | 1.50 ± 0.56 | 1.26 ± 0.58** | -16.2 ± 28.0 |
HDL cholesterol | 1.32 ± 0.26 | 1.43 ± 0.30*** | 8.03 ± 13.2 |
LDL cholesterol | 3.82 ± 0.67 | 2.37 ± 0.53*** | -38.0 ± 10.3 |
TC/HDLC Ratio | 4.53 ± 0.89 | 3.17 ± 0.63*** | -30.1 ± 9.79 |